BridgeBio Pharma (BBIO) Total Liabilities (2018 - 2026)

BridgeBio Pharma has reported Total Liabilities for 9 years, with the latest figure at $3.6 billion in Q1 2026.

• Quarterly Total Liabilities rose 44.42% year-over-year to $3.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 billion (up 44.42% YoY) and the FY2025 annual result came in at $3.0 billion, up 26.74% from the prior year.
• Total Liabilities climbed to $3.6 billion in Q1 2026 per BBIO's latest filing, from $3.0 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $3.6 billion in Q1 2026 and troughed at $1.8 billion in Q1 2023.
• A 5-year average of $2.2 billion and a median of $1.9 billion in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities slipped 1.28% in 2023, then jumped 55.09% in 2025.
• Over 5 years, Total Liabilities stood at $1.9 billion in 2022, then increased by 1.12% to $1.9 billion in 2023, then grew by 25.84% to $2.4 billion in 2024, then climbed by 26.74% to $3.0 billion in 2025, then advanced by 20.82% to $3.6 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $3.6 billion, $3.0 billion, and $2.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.